Is there a directional genetic and transcriptomic association between major depressive disorder and the risk of myocardial infarction and heart failure?
Mendelian randomization and transcriptome analysis identify a directional association between depression and increased risk of MI and HF, revealing specific immune endotypes as potential therapeutic targets.
Genetic, epidemiological, and multi-omic evidence supports a directional association between MDD and increased risk of MI and HF. We deliver reproducible blood-based gene panels and immune endotypes that dissect biologically distinct MDD-CVD substructures, offering actionable targets for precision immunomodulatory therapy in cardio-depressive comorbidity.
Zhou et al. (2026) studied this question.